180 related articles for article (PubMed ID: 34127480)
1. Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient Screening.
Lalazar G; Requena D; Ramos-Espiritu L; Ng D; Bhola PD; de Jong YP; Wang R; Narayan NJC; Shebl B; Levin S; Michailidis E; Kabbani M; Vercauteren KOA; Hurley AM; Farber BA; Hammond WJ; Saltsman JA; Weinberg EM; Glickman JF; Lyons BA; Ellison J; Schadde E; Hertl M; Leiting JL; Truty MJ; Smoot RL; Tierney F; Kato T; Wendel HG; LaQuaglia MP; Rice CM; Letai A; Coffino P; Torbenson MS; Ortiz MV; Simon SM
Cancer Discov; 2021 Oct; 11(10):2544-2563. PubMed ID: 34127480
[TBL] [Abstract][Full Text] [Related]
2. Targeting BCL-XL in fibrolamellar hepatocellular carcinoma.
Shebl B; Ng D; Lalazar G; Rosemore C; Finkelstein TM; Migler RD; Zheng G; Zhang P; Jiang CS; Qureshi A; Vaughan R; Yarchoan M; de Jong YP; Rice CM; Coffino P; Ortiz MV; Zhou D; Simon SM
JCI Insight; 2022 Sep; 7(17):. PubMed ID: 36073545
[TBL] [Abstract][Full Text] [Related]
3. A novel therapeutic combination sequentially targeting aurora B and Bcl-xL in hepatocellular carcinoma.
Matsunaga H; Tanaka S; Aihara A; Ogawa K; Matsumura S; Ban D; Ochiai T; Irie T; Kudo A; Nakamura N; Arii S; Tanabe M
Ann Surg Oncol; 2015 Sep; 22(9):3079-86. PubMed ID: 25524010
[TBL] [Abstract][Full Text] [Related]
4. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
[TBL] [Abstract][Full Text] [Related]
5. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
[TBL] [Abstract][Full Text] [Related]
6. A combinatorial drug screen in PDX-derived primary rhabdomyosarcoma cells identifies the NOXA - BCL-XL/MCL-1 balance as target for re-sensitization to first-line therapy in recurrent tumors.
Manzella G; Moonamale DC; Römmele M; Bode P; Wachtel M; Schäfer BW
Neoplasia; 2021 Sep; 23(9):929-938. PubMed ID: 34329950
[TBL] [Abstract][Full Text] [Related]
7. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA.
Hirsch TZ; Negulescu A; Gupta B; Caruso S; Noblet B; Couchy G; Bayard Q; Meunier L; Morcrette G; Scoazec JY; Blanc JF; Amaddeo G; Nault JC; Bioulac-Sage P; Ziol M; Beaufrère A; Paradis V; Calderaro J; Imbeaud S; Zucman-Rossi J
J Hepatol; 2020 May; 72(5):924-936. PubMed ID: 31862487
[TBL] [Abstract][Full Text] [Related]
8. Establishment of a Patient-Derived Xenograft Tumor From Hepatitis C-Associated Liver Cancer and Evaluation of Imatinib Treatment Efficacy.
Nazzal M; Sur S; Steele R; Khatun M; Patra T; Phillips N; Long J; Ray R; Ray RB
Hepatology; 2020 Aug; 72(2):379-388. PubMed ID: 32356575
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses.
Karpel-Massler G; Ishida CT; Bianchetti E; Shu C; Perez-Lorenzo R; Horst B; Banu M; Roth KA; Bruce JN; Canoll P; Altieri DC; Siegelin MD
Cancer Res; 2017 Jul; 77(13):3513-3526. PubMed ID: 28522750
[TBL] [Abstract][Full Text] [Related]
10. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.
Leverson JD; Phillips DC; Mitten MJ; Boghaert ER; Diaz D; Tahir SK; Belmont LD; Nimmer P; Xiao Y; Ma XM; Lowes KN; Kovar P; Chen J; Jin S; Smith M; Xue J; Zhang H; Oleksijew A; Magoc TJ; Vaidya KS; Albert DH; Tarrant JM; La N; Wang L; Tao ZF; Wendt MD; Sampath D; Rosenberg SH; Tse C; Huang DC; Fairbrother WJ; Elmore SW; Souers AJ
Sci Transl Med; 2015 Mar; 7(279):279ra40. PubMed ID: 25787766
[TBL] [Abstract][Full Text] [Related]
11. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
12. Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems.
Shang E; Zhang Y; Shu C; Ishida CT; Bianchetti E; Westhoff MA; Karpel-Massler G; Siegelin MD
Sci Rep; 2018 Oct; 8(1):15383. PubMed ID: 30337641
[TBL] [Abstract][Full Text] [Related]
13. The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma.
Shimizu S; Takehara T; Hikita H; Kodama T; Miyagi T; Hosui A; Tatsumi T; Ishida H; Noda T; Nagano H; Doki Y; Mori M; Hayashi N
J Hepatol; 2010 May; 52(5):698-704. PubMed ID: 20347499
[TBL] [Abstract][Full Text] [Related]
14. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.
Faber AC; Farago AF; Costa C; Dastur A; Gomez-Caraballo M; Robbins R; Wagner BL; Rideout WM; Jakubik CT; Ham J; Edelman EJ; Ebi H; Yeo AT; Hata AN; Song Y; Patel NU; March RJ; Tam AT; Milano RJ; Boisvert JL; Hicks MA; Elmiligy S; Malstrom SE; Rivera MN; Harada H; Windle BE; Ramaswamy S; Benes CH; Jacks T; Engelman JA
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1288-96. PubMed ID: 25737542
[TBL] [Abstract][Full Text] [Related]
15. Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver.
El Dika I; Bowman AS; Berger MF; Capanu M; Chou JF; Benayed R; Zehir A; Shia J; O'Reilly EM; Klimstra DS; Solit DB; Abou-Alfa GK
Cancer; 2020 Sep; 126(18):4126-4135. PubMed ID: 32663328
[TBL] [Abstract][Full Text] [Related]
16. Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-X
Oh Y; Jung HR; Min S; Kang J; Jang D; Shin S; Kim J; Lee SE; Sung CO; Lee WS; Lee C; Jeong EM; Cho SY
Cancer Lett; 2021 Jan; 497():123-136. PubMed ID: 33068701
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Evaluation of AMG 337, a Highly Selective Small Molecule MET Inhibitor, in Hepatocellular Carcinoma.
Du Z; Caenepeel S; Shen Y; Rex K; Zhang Y; He Y; Tang ET; Wang O; Zhong W; Zhou H; Huang J; Huang E; Hu L; Coxon A; Zhang M
Mol Cancer Ther; 2016 Jun; 15(6):1227-37. PubMed ID: 27196749
[TBL] [Abstract][Full Text] [Related]
18. A case of fibrolamellar cancer with a palliative response and minor radiographic regression with erlotinib and bevacizumab combination therapy.
Fakih M
Am J Ther; 2014; 21(6):e207-10. PubMed ID: 23676344
[TBL] [Abstract][Full Text] [Related]
19. A Combinatorial CRISPR-Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment.
Xu F; Tong M; Tong CSW; Chan BKC; Chu HY; Wong TL; Fong JHC; Cheung MSH; Mak KH; Pardeshi L; Huang Y; Wong KH; Choi GCG; Ma S; Wong ASL
Cancer Res; 2021 Dec; 81(24):6219-6232. PubMed ID: 34666996
[TBL] [Abstract][Full Text] [Related]
20. Microarray profiling shows distinct differences between primary tumors and commonly used preclinical models in hepatocellular carcinoma.
Wang W; Iyer NG; Tay HT; Wu Y; Lim TK; Zheng L; Song IC; Kwoh CK; Huynh H; Tan PO; Chow PK
BMC Cancer; 2015 Oct; 15():828. PubMed ID: 26520397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]